A Phase III Study for 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody
(601) with Ranibizumab in patients with macular edema secondary to BRVO